Phase 1a/1b study of the safety, pharmacokinetics, and antitumor activity of ziftomenib in combination with imatinib in patients with advanced gastrointestinal stromal tumors (GIST) after imatinib failure.

Category Primary study
Conference2025 ASCO Annual Meeting I
Year 2025
This article has no abstract
Epistemonikos ID: 6e991576fbcbb46521cfe5786646a1580b9354e2
First added on: Sep 03, 2025